Splenic marginal zone lymphoma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Splenic marginal zone lymphoma}} | {{Splenic marginal zone lymphoma}} | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}}{{Affan}}, {{AS}} | ||
==Overview== | ==Overview== | ||
Laboratory tests for splenic marginal zone lymphoma include [[complete blood count]] (CBC), blood chemistry studies, [[ | Laboratory tests for [[splenic marginal zone lymphoma]] ([[SMZL]]) include [[complete blood count]] (CBC), blood chemistry studies, [[immunohistochemistry]], [[genetic testing]], [[flow cytometry]], [[FISH]], [[PCR]], and [[immunophenotyping]]. | ||
==Laboratory tests== | ==Laboratory tests== | ||
Laboratory tests for [[splenic marginal zone lymphoma]] [[(SMZL)]] include:<ref name=”seer”>Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22,2015</ref> | Laboratory tests for [[splenic marginal zone lymphoma]] [[(SMZL)]] include:<ref name="”seer”">Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22,2015</ref> | ||
* [[Complete blood count]] (CBC) with differential count | * [[Complete blood count]] (CBC) with differential count | ||
** [[Pancytopenia]] or leukemic presentation with [[leukocytosis]], [[anemia]], [[thrombocytopenia]]<ref name="pmid23484698">{{cite journal |vauthors=Yang SM, Jiang Q, Jiang B, Chen DB, Wang J, Jiang H, Lu J, Lu XJ, Bao L, Shi HX, Liu YR, Huang XJ |title=[Clinical characteristics of splenic marginal zone lymphoma with abnormal complete blood count] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=21 |issue=1 |pages=87–94 |date=February 2013 |pmid=23484698 |doi=10.7534/j.issn.1009-2137.2013.01.019 |url=}}</ref> | ** [[Pancytopenia]] or leukemic presentation with [[leukocytosis]], [[anemia]], [[thrombocytopenia]]<ref name="pmid23484698">{{cite journal |vauthors=Yang SM, Jiang Q, Jiang B, Chen DB, Wang J, Jiang H, Lu J, Lu XJ, Bao L, Shi HX, Liu YR, Huang XJ |title=[Clinical characteristics of splenic marginal zone lymphoma with abnormal complete blood count] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=21 |issue=1 |pages=87–94 |date=February 2013 |pmid=23484698 |doi=10.7534/j.issn.1009-2137.2013.01.019 |url=}}</ref> | ||
* [[Serum albumin]] levels | * [[Serum albumin]] levels | ||
* serum [[LDH]] levels | * serum [[LDH]] levels | ||
* [[Beta-2- microglobulin]] | * [[Beta-2-microglobulin]] | ||
* [[Immunohistochemistry]] | * [[Immunohistochemistry]]<ref name="pmid9777389">{{cite journal |vauthors=Piris MA, Mollejo M, Campo E, Menárguez J, Flores T, Isaacson PG |title=A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma |journal=Histopathology |volume=33 |issue=3 |pages=230–9 |date=September 1998 |pmid=9777389 |doi= |url=}}</ref> | ||
** Typically positive for [[CD20]],[[CD79a]], BCL-2 and [[immunoglobuin M]] ([[IgM]]. | ** Typically positive for [[CD20]],[[CD79a]], BCL-2 and [[immunoglobuin M]] ([[IgM]]). | ||
** Surface immunoglobulin D (IgD) and DBA44 are variably expressed. | ** Surface immunoglobulin D (IgD) and DBA44 are variably expressed. | ||
** Negative for [[CD5]], [[CD10]], [[CD43]], [[CD103]], CD123, [[Annexin A1]], BCL-6 and LEF-1. | ** Negative for [[CD5]], [[CD10]], [[CD43]], [[CD103]], CD123, [[Annexin A1]], BCL-6 and LEF-1. | ||
* [[Genetic testing]] | * [[Genetic testing]]<ref name="pmid25779943">{{cite journal |vauthors=Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC |title=Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing |journal=Clin. Cancer Res. |volume=21 |issue=18 |pages=4174–4183 |date=September 2015 |pmid=25779943 |pmc=4490180 |doi=10.1158/1078-0432.CCR-14-2759 |url=}}</ref> | ||
* Chromosomal 7q32 deletion (30-40%). | ** Chromosomal 7q32 deletion (30-40%). | ||
* Chromosome 3q gains (20-30%)). | ** Chromosome 3q gains (20-30%)). | ||
* NOTCH2 and KLF2 are the commonly reported gene mutations. | ** NOTCH2 and KLF2 are the commonly reported gene mutations. | ||
* [[Flow cytometry]]<ref name="pmid">{{cite journal |vauthors=Hu Y, Chen Y, Wang LH, Chen X, Fang F, Liu SQ, Wu XQ, Zhu P |title=[Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=22 |issue=2 |pages=349–56 |date=April 2014 |pmid= |doi=10.7534/j.issn.1009-2137.2014.02.016 |url=}}</ref> | * [[Flow cytometry]]<ref name="pmid">{{cite journal |vauthors=Hu Y, Chen Y, Wang LH, Chen X, Fang F, Liu SQ, Wu XQ, Zhu P |title=[Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=22 |issue=2 |pages=349–56 |date=April 2014 |pmid= |doi=10.7534/j.issn.1009-2137.2014.02.016 |url=}}</ref> | ||
* [[FISH]] ([[fluorescence in situ hybridization]])<ref name="pmid29228725">{{cite journal |vauthors=Yi S, Yan Y, Xiong W, Lv R, Yu Z, Liu W, Liu E, Li H, Liu H, Li Z, An G, Xu Y, Ru K, Zou D, Qiu L |title=Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region |journal=Oncotarget |volume=8 |issue=58 |pages=98757–98770 |date=November 2017 |pmid=29228725 |pmc=5716765 |doi=10.18632/oncotarget.21931 |url=}}</ref> | * [[FISH]] ([[fluorescence in situ hybridization]])<ref name="pmid29228725">{{cite journal |vauthors=Yi S, Yan Y, Xiong W, Lv R, Yu Z, Liu W, Liu E, Li H, Liu H, Li Z, An G, Xu Y, Ru K, Zou D, Qiu L |title=Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region |journal=Oncotarget |volume=8 |issue=58 |pages=98757–98770 |date=November 2017 |pmid=29228725 |pmc=5716765 |doi=10.18632/oncotarget.21931 |url=}}</ref> | ||
Latest revision as of 21:41, 30 January 2019
|
Splenic marginal zone lymphoma Microchapters |
|
Differentiating Splenic marginal zone lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Splenic marginal zone lymphoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Splenic marginal zone lymphoma laboratory findings |
|
Splenic marginal zone lymphoma laboratory findings in the news |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
|
Risk calculators and risk factors for Splenic marginal zone lymphoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Muhammad Affan M.D.[2], Sowminya Arikapudi, M.B,B.S. [3]
Overview
Laboratory tests for splenic marginal zone lymphoma (SMZL) include complete blood count (CBC), blood chemistry studies, immunohistochemistry, genetic testing, flow cytometry, FISH, PCR, and immunophenotyping.
Laboratory tests
Laboratory tests for splenic marginal zone lymphoma (SMZL) include:[1]
- Complete blood count (CBC) with differential count
- Pancytopenia or leukemic presentation with leukocytosis, anemia, thrombocytopenia[2]
- Serum albumin levels
- serum LDH levels
- Beta-2-microglobulin
- Immunohistochemistry[3]
- Typically positive for CD20,CD79a, BCL-2 and immunoglobuin M (IgM).
- Surface immunoglobulin D (IgD) and DBA44 are variably expressed.
- Negative for CD5, CD10, CD43, CD103, CD123, Annexin A1, BCL-6 and LEF-1.
- Genetic testing[4]
- Chromosomal 7q32 deletion (30-40%).
- Chromosome 3q gains (20-30%)).
- NOTCH2 and KLF2 are the commonly reported gene mutations.
- Flow cytometry[5]
- FISH (fluorescence in situ hybridization)[6]
- PCR[7]
References
- ↑ Splenic marginal zone lymphoma. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd5327/ Accessed on December 22,2015
- ↑ Yang SM, Jiang Q, Jiang B, Chen DB, Wang J, Jiang H, Lu J, Lu XJ, Bao L, Shi HX, Liu YR, Huang XJ (February 2013). "[Clinical characteristics of splenic marginal zone lymphoma with abnormal complete blood count]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 21 (1): 87–94. doi:10.7534/j.issn.1009-2137.2013.01.019. PMID 23484698.
- ↑ Piris MA, Mollejo M, Campo E, Menárguez J, Flores T, Isaacson PG (September 1998). "A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma". Histopathology. 33 (3): 230–9. PMID 9777389.
- ↑ Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC (September 2015). "Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing". Clin. Cancer Res. 21 (18): 4174–4183. doi:10.1158/1078-0432.CCR-14-2759. PMC 4490180. PMID 25779943.
- ↑ Hu Y, Chen Y, Wang LH, Chen X, Fang F, Liu SQ, Wu XQ, Zhu P (April 2014). "[Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 22 (2): 349–56. doi:10.7534/j.issn.1009-2137.2014.02.016.
- ↑ Yi S, Yan Y, Xiong W, Lv R, Yu Z, Liu W, Liu E, Li H, Liu H, Li Z, An G, Xu Y, Ru K, Zou D, Qiu L (November 2017). "Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region". Oncotarget. 8 (58): 98757–98770. doi:10.18632/oncotarget.21931. PMC 5716765. PMID 29228725.
- ↑ Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F (March 2015). "DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features". Blood. 125 (12): 1922–31. doi:10.1182/blood-2014-08-596247. PMC 4416938. PMID 25612624.